TW201417821A - Composition of antrodia camphorata and use thereof - Google Patents

Abstract

The present invention discloses a composition of antrodia camphorata, comprising: antrodia camphorata mycelium, olive extracts, and coenzymes (Co Q10). The antrodia camphorata accounting for 60% to 90%, the olive extracts accounting for 9% to 39%, and the coenzymes 1% to 6% of the composition of antrodia camphorata.

Description

Antrodia camphora composition and its use

The present invention relates to an antrodia camphorata composition and its use, and more particularly to a composition of the antrodia camphorata comprising a burdock mycelium, an olive extract, and a coenzyme, and uses thereof.

Modern people's diet tends to be refined, and many high-oil, high-sugar, high-salt, heavy-tasting diets and lifestyles without exercise habits often lead to fatty liver. According to statistics conducted by the Department of Health in 2011, the prevalence of fatty liver in Taiwan is as high as 60%, which is a national health issue that needs to be addressed.

The cause of fatty liver is very complicated. It is generally considered to be classified into nonalcoholic fatty liver disease (NAFLD) caused by obesity, insulin resistance or metabolic syndrome, and alcoholic fatty liver caused by alcohol ( Alcoholic fatty liver disease, AFLD). In clinical studies, it has been found that chronic chronic inflammation of the liver is impaired and excessive triglycerides accumulate in the liver, which is the main cause of alcoholic fatty liver disease. However, many common liver diseases may be transformed by fatty liver disease, such as liver cirrhosis and liver cancer. Therefore, if the patient is treated or improved when suffering from fatty liver, the disease can be prevented from worsening.

In addition, in the treatment of liver health and liver disease, Antrodia has been considered to have anti-tumor and liver-protecting effects. Antrodia camphorata, also known as Antrodia camphorata or Burdock mushroom, is a fungus that grows on Taiwan's unique Burdock wood. At present, the market is commonly used in the production of health care products using materials such as the body extract of Antrodia camphorata or its extract, the fermentation filtrate of Antrodia camphorata, and the like, which have good effects in anti-tumor and liver protection, and are treated in various other liver-related diseases. Has great potential with health care. Accordingly, the present invention conducts an experimental study using a predetermined proportion of the Antrodia camphorata composition, and hopes to develop a composition formulation having an effect of improving fatty liver.

In view of the above-mentioned problems of the prior art, it is an object of the present invention to provide a composition of Antrodia camphorata comprising mycelium of Antrodia camphorata, olive extract, and coenzyme (Co Q10), which accounts for 60% of the mycelium 90%, the olive extract accounts for 9% to 39%, and the coenzyme accounts for 1% to 6%.

Among them, the Antrodia camphorata composition of the present invention may be in the form of a powder, a granule or a liquid.

Further, the Antrodia camphorata composition of the present invention may be in the form of a tablet, a capsule, a granule, a pill, a tablet, or a powder.

The Antrodiabum composition of the present invention may comprise a pharmaceutically or food-acceptable excipient selected from the group consisting of a flavoring agent, a sweetener, a preservative, an antioxidant, a chelating agent, a penetrant, a lubricant, A group consisting of a lozenge adjuvant, a coloring agent, a moisturizer, a binding agent, and a pharmaceutically compatible carrier.

Another object of the invention is to provide a use of an Antrodia camphora composition. This use involves lowering the level of glutamate acetate transaminase (GOT) and glutamate pyruvate transaminase (GPT) in serum. In addition, the use also includes lowering the serum low-density lipoprotein content and increasing the high-density lipoprotein content in the serum. This use also includes inhibition of liver hypertrophy.

The use of the Antrodia camphorata composition of the present invention comprises improving liver function, reducing liver damage, and lowering blood lipids.

In view of the above, the Antrodia camphorata composition of the present invention and its use may have one or more of the following advantages:

(1) The Antrodia camphorata composition of the present invention comprises a predetermined proportion of the mycelium of Antrodia camphorata, olive extract, and coenzyme, which can effectively reduce the serum GOT/GPT value after liver damage and enhance the activity of liver antioxidant enzymes, The effect of protecting the liver.

(2) The Antrodia camphorata composition of the present invention comprises a predetermined proportion of A. angustifolia mycelium, an olive extract, and a coenzyme, which can effectively lower blood cholesterol concentration and tissue lipid peroxidation, and has an effect of improving fatty liver.

no

Fig. 1A and Fig. 1B show the effect of the composition of the Antrodia camphorata composition of the present invention on the liver function index of mice after chemical liver injury.

Fig. 2A and Fig. 2B show the effect of the composition of the Antrodia camphorata composition on the liver enzyme activity of mice after chemical liver injury.

Fig. 3 is a view showing the effect of the composition of the Antrodia camphorata composition of the present invention on liver hypertrophy caused by alcoholic fatty liver in mice.

4A to 4D are views showing the effect of the composition of the Antrodia camphorata composition of the present invention on blood cholesterol in mice suffering from alcoholic fatty liver.

Figures 5A and 5B show the effect of the Antrodia camphora composition of the present invention on the activity of enzymes in the liver of mice suffering from alcoholic fatty liver.

6A to 6D are views showing the effects of the Antrodia camphorata composition of the present invention on liver, kidney, and cardiovascular lipid peroxidation in mice suffering from alcoholic fatty liver.

Figure 7 is a schematic diagram showing the pathological section of mouse liver tissue.

8A to 8E are views showing the effect of the Antrodia camphora composition of the present invention on the antioxidant ability of the liver of a mouse having alcoholic fatty liver.

The invention will be further described in detail by the following preferred embodiments and the accompanying drawings. It should be noted that the experimental data disclosed in the following embodiments are for explaining the technical features of the present invention, and are not intended to limit the manner in which they can be implemented.

The Antrodia camphorata composition disclosed in the present invention may comprise Antrodia camphorata mycelium, olive fruit extract, and coenzyme (CoQ10). Among them, the mycelium of Antrodia camphorata was obtained by directly scraping the mycelium from the burdock, and it was pointed out in the research that it has the functions of protecting the liver and regulating immunity. The olive fruit extract is derived from olive nuts, and its main active ingredient is hydroxytryosol, which has antioxidant and hypolipidemic effects. In addition, Coenzyme Q10 is a potent oil-soluble antioxidant that is currently used to prevent or treat heart disease. The Antrodia camphorata mycelium, the olive fruit extract, and the coenzyme Q10 contained in the Antrodia camphorata composition of the present invention account for 60% to 90%, 9% to 39%, and 1% to 6%, respectively, of the composition. Preferably, they are 70% to 80%, 19% to 28%, and 2% to 5%, respectively.

In order to understand and confirm the use of the Antrodiabum composition of the present invention for improving liver function, reducing liver damage, and lowering blood lipids, it will be described in detail below by animal experiments of different examples.

First, in order to evaluate the liver-protecting effect of the Antrodia camphorata composition of the present invention against chemical liver damage caused by carbon tetrachloride (CCl4), in this example, Balb/c mice were divided into five groups as experimental subjects. , respectively: (1) control group; (2) carbon tetrachloride; (3) carbon tetrachloride + silymarin (200 mg / kg); (4) carbon tetrachloride + the combination of the invention (30 mg/kg); and (5) carbon tetrachloride + the Antrodia camphora composition of the present invention (300 mg/kg). Among them, carbon tetrachloride was destroyed by chemical liver injury by subcutaneous injection at the first, third and sixth weeks (wherein carbon tetrachloride was dissolved in corn oil, and the concentration of the mice administered to the mice was 0.4 μl/100 g BW). The silymarin and the anatase composition of the present invention are administered to the test sample one week before the carbon tetrachloride-induced liver injury. In this example, the test was performed for 8 weeks, and the tail artery blood sampling method was performed every week to measure the liver function index (GPT/GOT) in the serum, and fasted for 24 hours before blood collection, and sacrificed at the 9th week. Mouse liver to detect liver enzyme activity.

Among them, silymarin is currently known as a herbal medicine for repairing liver cells and enhancing liver function, and has certain effects on hepatitis and fatty liver, and is used as a positive control group.

The above results are shown in Figs. 1A, 1B, 2A, and 2B. Fig. 1A and Fig. 1B show the effect of the composition of the Antrodia camphorata composition of the present invention on the liver function index of mice after chemical liver injury. Fig. 2A and Fig. 2B show the effect of the composition of the Antrodia camphorata composition on the liver enzyme activity of mice after chemical liver injury.
[0028] Referring to Figures 1A and 1B, it was found that the GPT/GOT content in the serum of each group began to rise in the second week. At the 5th to 6th week, the GPT/GOT content in the serum of the second group was significantly greater than that of the other groups, indicating that the carbon tetrachloride used in the present example did induce chemical liver damage and caused liver. The functional index has increased. As shown in Fig. 1A and Fig. 1B, at the sixth week, the GPT/GOT content in the serum of the third to fifth groups all decreased. However, the change in GPT/GOT content in the serum of Group 5 was similar to that of Group 3 (positive control group), and decreased to the GPT/GOT content near the uninduced chemical liver injury at Week 8. This result shows that the use of the Astragalus lucidum composition of the present invention does effectively reduce the GPT/GOT value in serum.

Referring to Figures 2A and 2B, the activity of catalase in Groups 3 to 5 was increased compared to Group 2, and both were upgraded to Group 1 (control group). Similar activity, and the antioxidant activity of superoxide dismutase (SOD) in Groups 3 to 5 was significantly higher than that in Group 2.

Next, the efficacy of the Antrodiabum composition of the present invention for improving fatty liver will be described.

In the present example, 8 to 10 weeks old C57BL/6J (B6) male rats were divided into the following six groups: (1) a control group for feeding a normal diet, and (2) a high cholesterol diet (HCD), (3) High cholesterol diet + Hydroxytyrosol (2.5 mg/kg), (4) High cholesterol diet + Olive polyphenols (5 mg/kg), (5) High cholesterol diet + Astragalus lucidum composition of the present invention (250) Mg/kg), (6) High cholesterol diet + the Antrodia camphora composition of the present invention (500 mg/kg). In the present example, the above-mentioned group was assigned to feed for four weeks, and blood was collected daily for serum detection, and the liver was examined at the 4th week for liver weight detection, liver enzyme activity detection, peroxidation index detection, and vascular tissue sectioning.

Among them, the high-cholesterol diet is supplemented with Lieber-DeCarli liquid alcohol diet in the diet to induce alcoholic fatty liver in mice. The olive polyphenols are currently known to have anti-oxidation and hypolipidemic effects, and are used as a positive control group.

Since liver hypertrophy occurs in mice with alcoholic fatty liver, the liver weight of the mouse obtained through the above experimental procedure is first compared with the body weight thereof, and the results are shown in Fig. 3. Fig. 3 is a view showing the effect of the composition of the Antrodia camphorata composition of the present invention on liver hypertrophy caused by alcoholic fatty liver in mice. In Fig. 3, it can be found that compared with the second group, the fifth group and the sixth group (i.e., feeding different doses of the Astragalus lucidum composition of the present invention) can effectively inhibit liver hypertrophy caused by alcoholic fatty liver. The phenomenon.

Next, the blood cholesterol levels in the mice in each group were examined. Two hours after administration of the Antrodia camphorata composition, the mice were tested for total cholesterol (low cholesterol), low-density lipoprotein (LDL), and high-density lipoprotein (high-density) by blood sampling in the tail vein every week. Density lipoprotein, HDL), and Atherogenic index (AI). The results are shown in Figures 4A to 4D. 4A to 4D are views showing the effect of the composition of the Antrodia camphorata composition of the present invention on blood cholesterol in mice suffering from alcoholic fatty liver.

Referring to Figure 4A, Groups 5 and 6 reduced total cholesterol levels in the blood compared to Group 2. Referring to Figures 4B and 4C, compared with Group 2, Groups 5 and 6 can reduce the amount of LDL in the blood and increase the HDL content, and the effect of the higher dose group. It is better. Among them, the effect of the Antrodia camphorata composition of the present invention on lowering the content of LDL in the blood is better than the group of feeding the olive polyphenol alone.

Referring also to Figure 4D, Group 6 (i.e., the Astragalus lucidum composition of the present invention at a feeding dose of 500 mg/kg) significantly reduced the arteriosclerosis index, and the magnitude of the decrease was similar to that of the second group. The group of olive polyphenols shows that the Antrodia camphorata composition of the present invention is indeed effective in lowering blood cholesterol levels.

Next, the activities of catalase and antioxidant enzyme superoxide dismutase in the liver of each group of mice were examined, and the activity assay of catalase and antioxidant enzyme superoxide dismutase in the liver will be described in detail below.

In the activity analysis of catalase (CAT), the liver tissue of the mouse was first washed with physiological saline, and the physiological saline was dropped on the funnel, and an appropriate amount of phosphate buffer solution was added, followed by breaking. Become a 10% homogenate. Next, after centrifugation at 700 xg for 10 minutes, the supernatant was taken, and the supernatant was added to 1% Triton X-100 in a ratio of 9:1 to obtain a stock homogenate (SH). The above SH was diluted with an appropriate amount of a phosphate buffer solution, and the pH was adjusted to pH 7 to obtain a dilute homogenate (DH). Then take 2 ml of DH, add 1 ml of H ₂ O ₂ (0.03 M), shake vigorously, and measure the absorbance (A) with a spectrophotometer at 25 ° C and 240 nm, every 15 seconds. The measurement was performed once, and the total measurement was performed twice, and the reaction rate constant K was calculated by the following formula.
K = (2.3 / Δt) log (Al / A2)
△T: time interval (15 seconds)
A1: T1 period, the absorbance of the sample - blank absorbance.
A2: T2 period, absorbance of the sample - blank absorbance.

Among them, liver tissue CAT activity is expressed as K per milligram of protein per unit protein.

In the superoxide dismutase (SOD) activity analysis, the liver tissue of the mouse was first washed with ice-cold saline, and the physiological saline was dripped on the funnel, followed by the addition. A suitable amount of buffer (0.32 Msucrose, 1 mM EDTA, 10 mM Tris-HCl, pH 7.4) was broken up to obtain a 10% homogenate. After centrifuging the above homogenate at 13600 xg for 30 minutes, 50 懲ml of the supernatant was added to 100 懲ml of Tris-cacodylic acid buffer (pH 8.2, 50 mM), and pure water was added to make the volume 980 懲ml. . Then add 20 懲ml of pyrogallol (0.2 mM), shake vigorously, and measure the absorbance (A) at 420 nm with a spectrophotometer, measure every 20 seconds for a total of 5 minutes, and Calculate ΔA/ΔT. Among them, the amount of enzyme that inhibits the auto-oxidation rate of pyrogallol by 50% per unit time is determined as one unit (U), and the SOD activity of liver tissue is expressed as the unit quantity of SOD per unit of protein (U per milligram of Protein). The result is shown in Fig. 5.

Figures 5A and 5B show the effect of the Antrodia camphora composition of the present invention on the activity of enzymes in the liver of mice suffering from alcoholic fatty liver. Referring to Figures 5A and 5B, Groups 5 and 6 promoted the activity of catalase and antioxidant enzyme superoxide dismutase in the liver, with higher doses. The group effect is better. From the above results, it was revealed that the Antrodia camphorata composition of the present invention can effectively enhance the activity of catalase and antioxidant enzyme superoxide dismutase in the liver.

Next, in order to examine the effects of the Antrodia camphorata composition of the present invention on liver, kidney, and cardiovascular lipid peroxidation in mice suffering from alcoholic fatty liver, liver, heart muscle, kidney, and blood vessels are also separately detected in this embodiment. The lipid peroxidation pressure index, the detection method thereof will be described in detail below.

First, the liver, kidney, and heart tissues of the mice were washed with physiological saline, and physiological saline was dripped on the funnel, and then an appropriate amount of phosphate buffer solution was added and broken up to obtain a 10% homogenized solution. Next, the lipid peroxidation index (TBARS) is measured. Here, MDA (malondialdehyde) is produced due to lipid peroxidation, and one molecule of MDA is combined with two molecules of TBA (thiobarbituric acid) to form pink TBARS (thiobarbituric acid). Reactivesubstance), therefore, the degree of lipid peroxidation is detected here by measuring the amount of TBARS production.

The tissue homogenized by the above method was added with 1 ml of 20 mg/ml BHT, 2 ml of 1% TBA, and 1 ml of 2.8% TCA, and heated in a water bath at 100 ° C for 20 minutes. After cooling, the absorbance at 532 nm was measured. . The higher the absorbance at 532 nm, the more MDA product is present. Therefore, if the Astragalus lucidum composition of the present invention lowers the absorbance of the system, it has an antioxidant effect, which can be calculated by the following formula:

Inhibition rate (%) = [absorbance value of control group - absorbance value of test group / absorbance value of control group] × 100 %

Among them, 1,1,3,3-tetra-methoxypropane can be hydrolyzed to MDA with 1 N of H ₂ SO ₄ , and the absorbance is measured by the same detection method to prepare a standard curve. The above standard curve is converted into the amount of MDA produced (mM), and the higher the amount of MDA produced, the worse the antioxidant effect.

The result is shown in Fig. 6. 6A to 6D are views showing the effects of the Antrodia camphorata composition of the present invention on liver, kidney, and cardiovascular lipid peroxidation in mice suffering from alcoholic fatty liver. Referring to Figures 6A to 6D, the results show that the Antrodia camphorata composition of the present invention can reduce the peroxidative stress index in liver tissue, myocardial tissue, kidney tissue, and blood vessels.

It can be seen from the above results that the Antrodia camphorata composition of the present invention can reduce liver hypertrophy caused by alcoholic fatty liver; effectively lower blood cholesterol content (including lowering total cholesterol, low density lipoprotein content, and increasing high density fat) Protein content); and reduction of lipid peroxidation in liver tissue, kidney tissue, myocardial tissue, and blood vessels. Therefore, the Antrodia camphorata composition of the present invention has an effect of improving fatty liver.

In order to evaluate the effect of different doses of the Antrodia camphorata composition of the present invention on alcoholic fatty liver, in another embodiment of the present invention, 50 male C57BL/6J (B6) of 7 weeks old weighing approximately 20 grams are first administered. The mice gradually increased the alcohol content of the feed to adapt the experimental animals to the liquid feed containing alcohol. After one week of adaptation, the mice were randomly divided into control group (C) (n=10, liquid non-alcoholic feed during the experiment), and liquid alcohol group (ALC) (n=). 40. Lieber-DeCarli liquid alcohol feed was given during the experiment. The liquid feed ingredient was replaced by alcohol according to 36% of the total calories required by the mice, and the alcoholic fatty liver animal model was established. Blood, measuring liver function index.

Then, during the experiment, in addition to the control group, the liquid alcohol diet group was randomly divided into 4 groups: alcohol group (ALC), low dose (0.2 g/kg) Antrodia camphorata composition group (ALC-L), medium dose ( 0.6 g/kg) Antrodia camphora composition group (ALC-M), high dose (1 g/kg) Antrodia camphora composition group (ALC-H), and during the experiment period (6 weeks), the food intake of each group was recorded every day. The results are shown in Table 1.

Table I

The above values are expressed as ± SEM.
The different abc values indicated for each row indicate significant differences (p<0.05).

As can be seen from Table 1, in the first week to the third week, the mice in the group given the alcoholic feed were less than the control group, however, at the 4th to the 6th week, the different doses of the Antrodia camphorata composition were administered. The food intake of the mice in the group was significantly higher than that in the alcohol group (ALC). From this result, it can be inferred that different doses of Antrodia camphorata composition can improve the loss of appetite caused by alcohol intake.

Next, fasting blood was collected for analysis after feeding for the sixth week of the experimental period, and the liver was taken for later analysis. Among them, the mouse fasting blood collection system first fasted the mice for 12 hours, anesthetized with ether every other day, and collected the blood vessels in the cheeks to collect the blood collection tubes containing the anti-coagulant (heparin). Place on ice, then centrifuge at 10 ° C, 3000 × g for 10 minutes, then use a micropipette to re-package the plasma into a new microcentrifuge tube and store in a -80 ° C freezer.

The liver of the mouse obtained through the above experimental procedure was weighed and compared with its own body weight, and the results are shown in Table 2.

Table II



The above values are expressed as ± SEM.
The different abc values indicated for each row indicate significant differences (p<0.05).

As shown in Table 2, in terms of body weight, mice in the ALC, ALC-L, ALC-M, and ALC-H groups weighed less than the control group; and in the liver weight and the ratio of liver weight to body weight, the ALC group The liver weight of the mice was significantly higher than that of the other groups, and the above results were significantly different (p<0.05). This result shows that different doses of the Antrodia camphorata composition of the present invention can inhibit liver hypertrophy caused by alcoholic fatty liver.

The blood of the mouse obtained through the above experimental procedure is the liver function index Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), plasma total cholesterol (TC), The numerical analysis of plasma triglyceride (TG) is shown in Tables 3 and 4.

Table 3



The above values are expressed as ± SEM.
The different abc values indicated for each row indicate significant differences (p<0.05).

Table 4



The above values are expressed as ± SEM.
The different abc values indicated for each row indicate significant differences (p<0.05).

As can be seen from Table 3 and Table 4, there was no significant difference in aspartate transaminase, alanine transaminase, plasma total cholesterol and plasma triglyceride in the blood of each group of mice at week 0. . At week 6, the aspartate transaminase, alanine transaminase, plasma total cholesterol, and plasma triglyceride levels in the blood of mice given only alcohol (ALC) were significantly higher. In the other groups, the above results were significantly different (p<0.05). This result shows that different doses of the Antrodia camphorata composition of the present invention can suppress the increase in liver function index and the increase in blood lipid concentration caused by alcoholic fatty liver.

The liver of each group of mice obtained by the above experiment was subjected to numerical analysis of liver triglyceride, and the liver was histopathologically sectioned to observe the accumulation of fatty oil droplets in the liver tissue. The results are shown in Table 5 and Figure 7. Show.

Table 5



The above values are expressed as ± SEM.
The different abcd values indicated for each row indicate significant differences (p<0.05).

As can be seen from Table 5, the liver triglyceride system of the mice given only the alcohol group (ALC) was significantly higher than the other groups, and was found in the group administered with different doses of the Antrodia camphorata composition. The higher the dose of the Antrodia camphorata composition, the more the triglyceride decreased in the liver of the mouse, and the triglyceride in the liver of the group administered with the high dose of the Antrodia camphorata composition There were no significant differences in the control group.

See also Figure 7, which is a schematic representation of the pathological section of the liver tissue of mice. Part A is the liver pathological section of the control group (C), the liver pathological section of the B part is the alcohol group (ALC), and the mouse liver pathology of the low-dose Astragalus membranaceus composition group (ALC-L). Sections, Part D are liver pathological sections of mice in the middle dose of Antrodia camphorata composition group (ALC-M), and liver pathological sections of mice in Part E are high doses of Antrodia camphorata composition group (ALC-H).

From the histopathological section of Fig. 7, it can be found that the accumulation of fatty oil droplets in the liver tissue of mice administered with different doses of the Antrodia camphorata group was significantly improved compared with the alcohol group (ALC), and the results were consistent with the results shown in Table 4. . Therefore, it can be seen from Tables 4 and 7 that different doses of the Antrodia camphorata composition of the present invention can improve the accumulation of liver fat caused by alcoholic fatty liver, and the higher dose of Antrodia camphorata composition for such liver The better the improvement of fat accumulation. From these results, it was revealed that the Antrodia camphorata composition of the present invention can effectively suppress the rise of blood triglyceride and the accumulation of liver fat caused by alcohol intake.

The liver of each group of mice obtained by the above experiment was analyzed for liver antioxidant capacity, wherein glutathione peroxidase (Gpx) activity and glutathione reductase (glutathione reductase) were detected in the liver. Grd) activity, total glutathione (GSH) value, superoxide dismutase (SOD) activity, and catalase (CAT) activity, the results are shown in Figures 8A-8E Show.

Figures 8A and 8E show the effect of the Antrodiabum composition of the present invention on the antioxidant capacity of the liver of mice with alcoholic fatty liver. Among them, in each of the diagrams, the different abc values indicated by each column diagram indicate significant differences (p<0.05).

It can be seen from Fig. 8A to Fig. 8E that the activity of the antioxidant index enzyme in the liver of the group administered with different doses of the Antrodia camphorata composition is higher than that of the alcohol group, indicating that the Astragalus lucidum composition of the present invention can be administered. Improves peroxidation damage caused by alcohol.

It can be seen from the above that different doses of the Antrodiabum composition of the present invention have a repairing effect on the damaged liver, which can lower the GOT/GPT value in the serum, increase the activity of the liver enzyme, and increase the activity of the antioxidant enzyme to increase The liver's ability to protect against peroxidative damage. In addition, different doses of the Astragalus lucidum composition of the present invention have the effects of lowering blood cholesterol and triglyceride content, reducing tissue lipid peroxidation, and improving liver fat droplet accumulation, thereby improving fatty liver, wherein The higher the dose of the Antrodia camphorata composition of the present invention, the better the effect of lowering the triglyceride in the blood.

In summary, the Antrodia camphorata composition of the present invention not only has a repairing effect on chemical liver damage, but also has a good repairing effect on liver damage caused by alcohol intake. In addition, different doses of Antrodia camphorata composition have an inhibitory effect on the liver function index, fat accumulation, and elevated blood lipid caused by alcoholic liver injury, and the higher dose of Antrodia camphora composition is caused by reducing alcohol intake. The improvement in blood triglyceride has a better improvement effect.

The above is intended to be illustrative only and not limiting. Any equivalent modifications or alterations to the spirit and scope of the invention are intended to be included in the scope of the appended claims.

no

Claims (10)

An anathopin composition comprising:
An anthraquinone mycelium, an olive extract, and a coenzyme (Co Q10), wherein the A. angustifolia mycelium accounts for 60% to 90%, the olive extract accounts for 9% to 39%, and the coenzyme accounts for 1%. 6%. The composition of the Antrodia camphorata according to claim 1, which is in the form of a powder, a granule or a liquid. The composition of the Antrodia camphorata according to claim 1, which is in the form of a tablet, a capsule, a granule, a pill, a tablet, or a powder. The composition of claim 27, wherein the composition further comprises a pharmaceutical or food acceptable excipient. The composition of claim 4, wherein the excipient is selected from the group consisting of a flavoring agent, a sweetener, a preservative, an antioxidant, a chelating agent, a penetrant, a lubricant, a lozenge adjuvant, A group of colorants, humectants, binders, and pharmaceutically compatible carriers. A use of the Antrodia camphorata composition as described in claim 1 of the patent application. The use according to claim 6 of the patent application further comprises reducing the content of glutamate acetic acid transaminase (GOT) and glutamic acid pyruvate transaminase (GPT) in a serum. The use of the invention as claimed in claim 6 further comprises lowering the low-density lipoprotein content in a serum and increasing the high-density lipoprotein content in the serum. The use as described in claim 6 of the patent application also includes inhibition of liver hypertrophy. For example, the use of the scope of the patent application includes improving liver function, reducing liver damage, lowering blood fat, and lowering blood cholesterol.